Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of 17-N-Allylamino-17-Demethoxy Geldanamycin (17-AAG, NSC #330507) Daily X 5 in Patients With Advanced Cancer Therapeutic Protocol

NCT00004065 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT00004065
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00004065 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of 17-N-Allylamino-17-Demethoxy Geldanamycin (17-AAG, NSC #330507) Daily X 5 in Patients With Advanced Cancer Therapeutic Protocol
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 1
Overall status
Completed
Start date
July 31, 1999
Completion date
March 31, 2005
Enrollment
Not reported
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, breast cancer, colorectal cancer, gastric cancer, head and neck cancer, kidney cancer, leukemia, lung cancer, melanoma (skin), ovarian cancer, prostate cancer, unspecified adult solid tumor, protocol specific